China Pharma Holdings vs Eyepoint
Eyepoint is the larger business, with $31.4m of revenue in fiscal 2025 against $4.1m for China Pharma Holdings (7.6 times as much). China Pharma Holdings grew faster (-8.5% against -27.5%). China Pharma Holdings kept more of each dollar of sales as profit: a net margin of -76.9% against -739.4%. Eyepoint carries less debt relative to equity (0.0% against 14.5%).
| Latest fiscal year | China Pharma HoldingsCPHI, 2025 | EyepointEYPT, 2025 |
|---|---|---|
| Revenue | $4.1m | $31.4m |
| Revenue growth | -8.5% | -27.5% |
| Net income | −$3.2m | −$232m |
| Operating margin | -78.2% | -776.0% |
| Net margin | -76.9% | -739.4% |
| Return on equity | -20.9% | -72.2% |
| Free cash flow | $88,937 | −$243m |
| Cash | $345,112 | $102m |
| Total debt | $3.3m | $0 |
| Debt to equity | 14.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 221 | 214 |
| Market value | $24.7m | $31.4m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 11 sales |